Allscripts approves Apixio Community Search product Apixio Inc.

‘Healthcare suppliers can coordinate care more effectively when they have instantaneous usage of records from other companies on the patient’s treatment team. Furthermore, provider companies can improve population wellness outcomes when given the capability to identify and action on specific groups of patients predicated on any given group of clinical metrics,’ stated Darren Schulte, CMO at Apixio. ‘Health care in the U.S. Is trending towards delivering higher quality and less expensive care, and Apixio’s answer when coupled with Sunrise from Allscripts might help healthcare institutions achieve these goals.’..End Points The primary end point was the %age of patients with an undetectable level of HCV RNA from week 4 through week 12 . Secondary end factors included the %age of sufferers with an HCV RNA level below the low limit of quantitation at week 4 , at week 12, and 12 weeks following the end of treatment . Virologic breakthrough during treatment was defined as a confirmed boost of 0.5 log10 IU per milliliter or even more above the nadir or a confirmed detectable level of HCV RNA in patients who previously had an undetectable degree of HCV RNA.